Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma

• Published in: Clinical genitourinary cancer 2016-12, Vol.14 (6), p.494-498
• Main Authors: Sonpavde, G., Pond, G.R., Di Lorenzo, G., Buonerba, C., Rozzi, A., Lanzetta, G., Necchi, A., Giannatempo, P., Raggi, D., Matsumoto, K., Choueiri, T.K., Mullane, S., Niegisch, G., Albers, P., Lee, J.L., Kitamura, H., Kume, H., Bellmunt, J.
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Agents - therapeutic use; Bridged-Ring Compounds - therapeutic use; Carcinoma, Transitional Cell - drug therapy; Chemotherapy; Female; Humans; Male; Middle Aged; Organoplatinum Compounds - therapeutic use; Overall survival; Prior platinum therapy; Prognosis; Salvage; Salvage Therapy - methods; Survival Analysis; Taxoids - therapeutic use; Treatment Outcome; Urologic Neoplasms - drug therapy; Urothelial carcinoma
• ISSN: 1558-7673; 1938-0682
• DOI: 10.1016/j.clgc.2016.05.001

Prior platinum- versus non-platinum-based chemotherapy did not affect survival after controlling for major prognostic factors in patients receiving salvage systemic chemotherapy for advanced urothelial carcinoma. Exposure to prior platinum therapy should not be required for the inclusion of patients in trials of salvage systemic therapy. Trials of salvage therapy for advanced urothelial carcinoma have required prior platinum-based therapy. This practice requires scrutiny because non-platinum-based first-line therapy may be offered to cisplatin-ineligible patients. Data of patients receiving salvage systemic chemotherapy were collected. Data on prior first-line platinum exposure were required in addition to treatment-free interval, hemoglobin, Eastern Cooperative Oncology Group performance status, albumin, and liver metastasis status. Cox proportional hazard regression was used to evaluate their association with overall survival (OS) after accounting for salvage single-agent or combination chemotherapy. Data were obtained from 455 patients previously exposed to platinum-based therapy and 37 not exposed to platinum. In the group exposed to prior platinum therapy, salvage therapy consisted of a single-agent taxane (n = 184) or a taxane-containing combination chemotherapy (n = 271). In the group not exposed to prior platinum therapy, salvage therapy consisted of taxane or vinflunine (n = 20), 5-fluorouracil (n = 1), taxane-containing combination chemotherapy (n = 12), carboplatin-based combinations (n = 2), and cisplatin-based combinations (n = 2). The median OS for the prior platinum therapy group was 7.8 months (95% confidence interval, 7.0, 8.1), and for the group that had not received prior platinum therapy was 9.0 months (95% confidence interval, 6.0, 11.0; P = .50). In the multivariable analysis, prior platinum therapy versus no prior platinum exposure did not confer an independent impact on OS (hazard ratio, 1.10; 95% confidence interval, 0.75, 1.64; P = .62). Prior platinum- versus non-platinum-based chemotherapy did not have a prognostic impact on OS after accounting for major prognostic factors in patients receiving salvage systemic chemotherapy for advanced urothelial carcinoma. Lack of prior platinum therapy should not disqualify patients from inclusion onto trials of salvage therapy.